List of Excipients in Branded Drug PRAVASTATIN

Generic Drugs Containing PRAVASTATIN

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	pravastatin sodium	0615-7570	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY Inc dba Vangard Labs	pravastatin sodium	0615-7570	CROSCARMELLOSE SODIUM
NCS HealthCare of KY Inc dba Vangard Labs	pravastatin sodium	0615-7570	CROSPOVIDONE

What are the Most Frequently-Used Excipients in PRAVASTATIN?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE

Pravastatin Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Pravastatin is a mature, off-patent statin with broad generic availability and limited conventional product differentiation. Commercial opportunity is concentrated in low-cost, robust immediate-release tablets, patient-friendly dosage forms, combination products, and manufacturing platforms that improve stability, dissolution, swallowing, or supply reliability. Excipient selection should prioritize pravastatin sodium stability, blend uniformity, rapid dissolution, tablet robustness, and bioequivalence.

What is the regulatory and commercial status of pravastatin?

Pravastatin sodium is an HMG-CoA reductase inhibitor marketed for hypercholesterolemia, mixed dyslipidemia, cardiovascular risk reduction, and selected pediatric lipid disorders. The reference product is Pravachol, originally marketed by Bristol-Myers Squibb. The FDA approved Pravachol in 1991, and generic pravastatin sodium tablets are now widely available across multiple strengths.[1]

Attribute	Pravastatin sodium
Therapeutic class	HMG-CoA reductase inhibitor
Common strengths	10 mg, 20 mg, 40 mg, 80 mg
Primary dosage form	Immediate-release tablet
Reference product	Pravachol
FDA approval	1991
Current market structure	Generic-dominated
Biosimilar exposure	None
Primary regulatory pathway	Abbreviated New Drug Application
Main commercial constraint	Low unit price and high generic competition
Main product opportunity	Differentiated oral delivery and efficient manufacturing

The market is primarily volume-driven. A new entrant generally needs a cost advantage, reliable supply, a differentiated dosage form, or access to a channel such as long-term care, government procurement, pediatric care, or international markets.

Current public FDA records do not indicate an active, commercially material exclusivity period for pravastatin sodium tablets. Reference-product patents and regulatory exclusivities have expired, leaving formulation, manufacturing, trademark, and market-access strategies as the principal sources of competitive advantage.[2]

What excipients are used in pravastatin tablets?

Pravastatin tablet formulations commonly use conventional diluents, binders, disintegrants, lubricants, glidants, and film-coating systems. Exact inactive ingredients vary by manufacturer and strength.

Excipient function	Common candidates	Commercial purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Controls tablet weight, compression, and cost
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Film former	Hypromellose, polyvinyl alcohol	Improves handling and appearance
Plasticizer	Polyethylene glycol, triacetin	Improves coating flexibility
Opacifier or colorant	Titanium dioxide, iron oxides, permitted pigments	Supports identification and light protection
pH or microenvironment modifier	Selected alkaline or buffering agents	May support chemical stability

FDA labeling records show that inactive ingredients differ among approved pravastatin products. A formulation proposed for development should therefore be assessed against the FDA Inactive Ingredient Database, the applicable USP-NF monographs, and the inactive-ingredient information for the reference product.[3,4]

How does pravastatin chemistry affect excipient selection?

Pravastatin is marketed as the sodium salt. It is more hydrophilic than several other statins, including simvastatin and atorvastatin, which affects both formulation design and competitive positioning.

The main formulation considerations are:

1. Pravastatin sodium must remain chemically stable during granulation, compression, coating, and storage.
2. The formulation must provide rapid and reproducible dissolution.
3. Low-dose strengths require strong content-uniformity controls.
4. The product must avoid unnecessary excipient complexity because the commercial price is low.
5. Coating and packaging should control moisture and protect tablet appearance.

A hydrophilic active can have favorable dissolution behavior, but high aqueous solubility does not eliminate the need for careful excipient screening. Water activity, granulation temperature, drying conditions, residual moisture, and blend residence time can affect stability and process performance.

Acidic microenvironments should be evaluated during compatibility testing because pravastatin can undergo degradation or conversion reactions under unfavorable pH conditions. Compatibility work should compare lactose-based, cellulose-based, and phosphate-based diluent systems rather than assuming that a standard statin formulation will transfer directly.

Which excipients are strongest candidates for a conventional tablet?

A practical first-line formulation platform would use microcrystalline cellulose or lactose as the principal diluent, crospovidone or croscarmellose sodium as the disintegrant, povidone or copovidone as the binder, and magnesium stearate or sodium stearyl fumarate as the lubricant.

Microcrystalline cellulose can improve compactibility and reduce dependence on wet granulation. Lactose can lower formulation cost and support high-throughput tableting, but its compatibility and moisture behavior require assessment. Dibasic calcium phosphate may improve mechanical strength, although it can alter dissolution and may create compatibility issues with some drug substances.

Crospovidone is attractive for direct compression and rapid disintegration. Croscarmellose sodium can provide strong swelling-driven breakup but may be more sensitive to compression force and formulation moisture. Sodium starch glycolate is cost-effective but can produce variable performance if over-compressed or used at excessive levels.

Magnesium stearate is widely used but must be controlled because over-lubrication can reduce tablet tensile strength and slow dissolution. Sodium stearyl fumarate may offer a useful alternative where magnesium stearate causes dissolution or compatibility problems.

What formulation strategies offer commercial differentiation?

Immediate-release tablets

Immediate-release tablets remain the lowest-risk and lowest-cost option. The strongest opportunity is a manufacturing platform that covers 10 mg, 20 mg, 40 mg, and 80 mg strengths with a common blend or proportional formula.

A common platform can reduce:

• Raw-material inventory
• Analytical method burden
• Scale-up work
• Cleaning validation complexity
• Packaging variation
• Batch-release cost

The principal technical risk is content uniformity in the 10 mg strength. A high-dose carrier system, ordered mixing, optimized particle-size distribution, or low-shear blending process may be required.

Film-coated tablets

Film coating provides limited clinical differentiation but can improve patient acceptance, product identification, abrasion resistance, and moisture protection. A thin hypromellose or polyvinyl alcohol coating is generally more commercially rational than a complex functional coating.

Color differentiation by strength can reduce medication errors in institutional settings. However, colorants can create supply and regulatory complications in international markets. A color-free or globally standardized coating system may reduce geographic variation.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with dysphagia, older adults, and selected pediatric patients. Pravastatin’s relatively low dose supports an ODT format, but taste masking remains a major development issue.

Potential excipient systems include:

• Mannitol for mouthfeel and cooling sensation
• Crospovidone or low-substituted hydroxypropyl cellulose for rapid disintegration
• Colloidal silicon dioxide to improve flow
• Sucralose, acesulfame potassium, or other sweeteners
• Flavoring agents
• Polymer-based taste-masking systems

The commercial value depends on demonstrating a meaningful patient or caregiver benefit. An ODT with a higher cost and no reimbursement advantage may struggle against inexpensive standard tablets.

Sprinkle or dispersible tablets

A dispersible or sprinkle product could address swallowing difficulty without the manufacturing complexity of a full ODT. The product must maintain dose uniformity when dispersed in a permitted vehicle or administered with soft food.

Key requirements include:

• Rapid dispersion
• Acceptable taste
• No significant drug adsorption to the vehicle
• No dose loss during administration
• Clear labeling for food compatibility
• Stability after reconstitution or dispersion

This strategy may be more practical for pediatric and geriatric channels than an ODT, but it requires a carefully controlled administration study and clear instructions.

Modified-release pravastatin

Modified-release pravastatin is technically possible but commercially less attractive. It would require evidence that altered exposure or dosing convenience improves clinical utility. The product would also face more demanding bioequivalence, food-effect, dissolution, and possibly clinical development requirements.

A modified-release product should not be pursued solely to create formulation patent claims. The commercial case would need to come from reduced dosing frequency, improved tolerability, or a specific patient population.

What formulation patents can protect pravastatin products?

Because the core pravastatin molecule and conventional tablet market are mature, new intellectual property would likely focus on:

• A narrowly defined excipient ratio
• A stability-improving microenvironment
• A taste-masking matrix
• A dispersible or orally disintegrating dosage form
• A multiparticulate or sprinkle formulation
• A manufacturing process that controls degradation
• A specific dissolution profile
• A packaging system combined with a stability result
• A fixed-dose combination containing pravastatin

Broad claims covering standard lactose, cellulose, disintegrant, lubricant, and film-coating combinations are likely to face substantial validity and obviousness pressure. Stronger patent positions would require a demonstrated technical effect, such as improved impurity control, unexpected stability, reduced variability, or clinically relevant administration advantages.

A formulation patent should be supported by comparative data against both the reference product and conventional generic formulations. Useful evidence includes accelerated stability, long-term stability, impurity profiling, dissolution across pH conditions, tablet mechanical testing, and bioequivalence.

When does pravastatin lose exclusivity and what is the Orange Book status?

Pravastatin’s original regulatory and patent exclusivity periods have expired. The product is therefore exposed to conventional generic competition rather than a pending loss-of-exclusivity event.

Exclusivity issue	Current assessment
New chemical entity exclusivity	Expired
Original reference-product patent protection	Expired
Active Orange Book patent barrier for standard tablets	No material current barrier identified
Paragraph IV exposure	Relevant mainly to any future listed formulation patent
ANDA pathway	Established and commercially active
Biosimilar pathway	Not applicable

The FDA Orange Book remains the controlling source for listed patents, certifications, and reference-product information. Any future differentiated pravastatin product with an Orange Book-listed patent could create Paragraph IV litigation risk, but standard generic pravastatin tablets do not depend on a live exclusivity event.[2]

Which companies are challenging pravastatin, and what is the litigation status?

Pravastatin is a mature generic market. Publicly significant current patent litigation involving standard pravastatin sodium tablets is not a primary market feature. Generic manufacturers compete through ANDA approvals, pricing, supply reliability, contracting, and portfolio breadth rather than through a live patent challenge to the original product.

A new formulation could change that profile. A sponsor seeking commercial exclusivity through a listed formulation patent would face potential Paragraph IV certifications from generic applicants. Settlement agreements could limit launch timing, but there is no current broad market settlement that controls ordinary pravastatin tablet entry.

How does pravastatin compare with competing statins?

Product	Relative formulation profile	Commercial implication
Pravastatin	Hydrophilic, immediate-release oral tablet; multiple generic strengths	Low-cost, tolerability-oriented positioning
Atorvastatin	Highly competitive generic market; broad strength range	Strong price pressure and limited differentiation
Simvastatin	Mature generic product with established tablet platforms	Low development risk, limited premium opportunity
Rosuvastatin	Potent, low-dose product with expanding generic use	Higher content-uniformity demands at low strengths
Fluvastatin	Smaller market and less common prescribing	Niche opportunity but lower volume

Pravastatin can be positioned where prescribers value a lower interaction burden or a more conservative statin profile. The product is less attractive for premium pricing because clinical substitution and generic availability are extensive.

What manufacturing and geographic opportunities exist?

The best manufacturing opportunity is a standardized, direct-compression or dry-granulation platform with strong control of blend uniformity and moisture. Wet granulation may be justified where powder flow or compression is poor, but it adds drying and stability controls.

Key manufacturing controls include:

• Active-particle-size distribution
• Sodium pravastatin assay and impurity profile
• Blend uniformity at the 10 mg strength
• Lubrication time
• Granulation endpoint or compaction force
• Residual moisture
• Tablet tensile strength and friability
• Dissolution across relevant pH conditions
• Packaging moisture protection

Geographic opportunity is strongest in markets with large generic volumes, fragmented supply, or demand for pediatric and dysphagia-friendly products. A global platform should limit excipients with complex regional acceptance issues and use suppliers qualified across the United States, European Union, and major regulated markets.

Packaging is a modest but practical differentiator. Unit-dose blister packaging can support adherence and institutional use. Bottles may offer lower cost for retail prescriptions. Moisture-barrier packaging should be selected based on stability data rather than assumed necessity.

What generic launch risks exist for pravastatin?

The main launch risks are commercial rather than patent-based.

Risk	Impact	Mitigation
Low selling price	Limits return on formulation investment	Use common platform and high-throughput manufacturing
Multiple approved suppliers	Increases price competition	Secure differentiated channels or supply contracts
10 mg content uniformity	Can delay development or scale-up	Optimize carrier and blending strategy early
Stability failure	Creates batch and shelf-life risk	Conduct compatibility and moisture studies before pivotal batches
Taste failure in ODT or sprinkle products	Reduces adherence and acceptance	Use human taste screening and robust masking
Excipient supply disruption	Interrupts production	Qualify dual suppliers and interchangeable grades
Formulation patent weakness	Limits exclusivity	Generate comparative technical data before filing
Limited reimbursement premium	Undermines differentiated product economics	Target institutional, pediatric, or specialty channels

What are the best commercial opportunities for pravastatin?

The most credible opportunities rank as follows:

1. A low-cost, multi-strength immediate-release platform with reliable supply.
2. A pediatric-friendly dispersible or sprinkle formulation.
3. An ODT for dysphagia-focused channels, if taste masking is successful.
4. A fixed-dose combination with another cardiovascular medicine, subject to clinical and regulatory feasibility.
5. Contract manufacturing using a validated common blend across strengths.
6. A stability-enhanced product for hot and humid markets.
7. Unit-dose packaging for hospitals, long-term care, and government procurement.

The weakest opportunity is a premium conventional tablet with no meaningful administration, stability, or supply advantage. The formulation would be easy to copy and difficult to price above established generics.

Key Takeaways

• Pravastatin sodium is an off-patent, generic-dominated product with no biosimilar exposure.
• Conventional immediate-release tablets offer the lowest regulatory and manufacturing risk.
• Excipient selection should focus on stability, blend uniformity, rapid dissolution, and cost.
• Microcrystalline cellulose, lactose, crospovidone, croscarmellose sodium, povidone, and standard film-coating systems are practical starting points, subject to compatibility testing.
• The 10 mg strength creates the greatest content-uniformity challenge.
• ODT and sprinkle products offer the clearest formulation differentiation but require taste-masking and administration evidence.
• Modified-release pravastatin has higher development risk and limited commercial justification.
• New patent value would need to come from a demonstrable technical effect, not a routine excipient substitution.
• The strongest commercial strategy combines a low-cost core product with targeted patient-friendly or institutional presentations.

FAQs

Is pravastatin sodium suitable for direct compression?

Yes. Direct compression can reduce processing steps and cost, but powder flow, low-dose content uniformity, lubricant sensitivity, and tablet robustness must be demonstrated across all strengths.

Which excipient is best for pravastatin tablet disintegration?

Crospovidone and croscarmellose sodium are leading candidates. The better choice depends on compression force, moisture, tablet porosity, dissolution targets, and compatibility with the selected diluent and binder.

Can pravastatin be developed as a pediatric liquid?

A liquid or suspension is technically possible, but chemical stability, taste, dose uniformity, preservative selection, and in-use stability would create a higher development burden than a tablet or dispersible dosage form.

Does pravastatin have an opportunity for a fixed-dose combination?

Potentially. A fixed-dose combination could improve adherence, but the active ingredients must have compatible dosing, stability, dissolution, manufacturing, and regulatory profiles. The market opportunity would depend on the selected cardiovascular partner.

What packaging is appropriate for pravastatin tablets?

High-density polyethylene bottles with desiccant or moisture-protective blister packaging are practical options. The final choice should follow formal stability data, supply-chain conditions, and the intended retail or institutional channel.

References

1. U.S. Food and Drug Administration. (1991). Pravachol: Prescribing information and original approval records. Drugs@FDA.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2025). Inactive ingredient database. FDA.

4. DailyMed. (2025). Pravastatin sodium tablet: Inactive ingredients and prescribing information. National Library of Medicine.

5. United States Pharmacopeia. (2025). USP-NF monograph: Pravastatin sodium. United States Pharmacopeial Convention.

6. U.S. Food and Drug Administration. (2016). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.